Lowe's Cos. (LOW): RONA Should Be Accretive in 2Q - UBS
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
UBS analyst, Michael Lasser, reiterated his Buy rating on shares of Lowe's (NYSE: LOW) along with his price target of $88.00 noting that the RONA deal is likely to be accretive to 2Q results.
LOW closed on its acquisition of RONA on May 20, so the Canadian retailer's financials should have a significant bearing on LOW's 2Q results. Herein, we lay out our combined estimates. For Lowe's, we model a 4.0% comp in 2Q, which is in-line with the cons. est. In addition, we forecast RONA will contribute an additional ~$780 mm in sales for the 70 days of 2Q since the deal closed. This equates to sales growth of 3.7% for RONA in the period after adjusting for FX. This is essentially in-line with the 3.4% adj. sales growth it experienced in 1Q. On our math, we expect the deal to be LSD accretive in the first year prior to closing (in-line with LOW's commentary), before accelerating to MSD accretion in year 2.
Shares of Lowe's closed at $80.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Starts Beacon Roofing Supply (BECN) at Buy
- BWS Financial Cuts Price Target on Sigma Designs (SIGM) to $5.00
- UPDATE: Oppenheimer Upgrades Envision Healthcare (EVHC) to Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesUBS, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!